Page 921 - Clinical Immunology_ Principles and Practice ( PDFDrive )

890 PARt SEVEN Organ-Specific Inflammatory Disease

34. Guptill JT, Soni M, Meriggioli MN. Current treatment, emergent 41. Miller RG, Barohn RJ, Dubinsky R. Expanding the evidence base for
translational therapies, and new therapeutic targets for autoimmune therapeutics in myasthenia gravis. Ann Neurol 2010;68:776.
myasthenia gravis. Neurother 2016;13:118. 42. Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis.
35. Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Autoimmunity 2010;43:428.
Neurosci Rep 2011;11:89. 43. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of
36. Olanow CW, Wechsler AS, Sirotkin-Roses M, et al. Thymectomy as prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia
primary therapy in myasthenia gravis. Ann NY Acad Sci 1987;505: Gravis Study Group. Neurology 1998;50:1778.
595. 44. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III,
37. Sonnett JR, Jaretzki A III. Thymectomy for Nonthymomatous Myasthenia randomized trial of mycophenylate mofetil in myasthenia gravis.
gravis: a critical analysis. Ann NY Acad Sci 2008;1132:315. Neurology 2008;71:400.
38. Johns TR. Long-term corticosteroid treatment of myasthenia gravis. Ann 45. The Muscle Study Group. A trial of mycophenylate mofetil with
NY Acad Sci 1987;505:568. prednisone as initial immunotherapy in myasthenia gravis. Neurology
39. Schneider-Gold C, Gadjos P, Toyka K, et al. Corticosteroids for 2008;71:394.
myasthenia gravis. Cochrane Database Syst Rev 2005;(18):CD002828. 46. Luo J, Lindstrom J. AChR-specific immunosuppressive therapy of
40. Seybold M. Plasmapheresis in myasthenia gravis. Ann NY Acad Sci myasthenia gravis. Biochem Pharmacol 2015;97:609.
1987;505:58.